Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 1 Interventional

Study of GS-1219 in Participants With HIV-1

ClinicalTrials.gov ID: NCT07115368

Public ClinicalTrials.gov record NCT07115368. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 12:01 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Umbrella Phase 1b, Open-label, Multi-Cohort Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Novel Antiretrovirals in Participants With HIV-1; Substudy-04: GS-1219

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is part of a master study. The goal of master protocol (GSUS-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy GS-US-544-5905-04 is to learn more about study drug GS-1219, safety, pharmacokinetics (PK) (how GS-1219 is absorbed, modified, distributed, and removed from the body of the participants), and antiviral activity in Participants With HIV-1.

Study identification

NCT ID
NCT07115368
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1
Lead sponsor
Gilead Sciences
Industry
Enrollment
4 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 10, 2025
Primary completion
Sep 18, 2025
Completion
Oct 1, 2025
Last update posted
Oct 20, 2025

2025

United States locations

U.S. sites
15
U.S. states
6
U.S. cities
12
Facility City State ZIP Site status
Ruane Clinical Research Group Los Angeles California 90036
Mills Clinical Research Los Angeles California 90069
Quest Clinical Research San Francisco California 94115
Washington Health Institute Washington D.C. District of Columbia 20017
Midland Florida Clinical Research Center DeLand Florida 32720
Midway Immunology and Research Center Ft. Pierce Florida 34982
BLISS Health Inc Orlando Florida 32803
Orlando Immunology Center Orlando Florida 32803
Triple O Research Institute West Palm Beach Florida 33407
Be Well Medical Center Berkley Michigan 48072
Central Texas Clinical Research Austin Texas 78705
Prism Health North Texas Dallas Texas 75208
North Texas Infectious Diseases Consultants Dallas Texas 75246
AXCES Research Group El Paso Texas 79902
AXCES Research Group Salt Lake City Utah 84102

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Recently updated HIV-1-infection trials

Other public records listing HIV-1-infection. Sorted by last update posted; newest first. Not a recommendation.

All HIV-1-infection trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07115368, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 20, 2025 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07115368 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →